# Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes | This GLP A target trial emulation found lower fracture risk on semaglutide only in the type 2 diabetes cohort | what a null in the cohort without diabetes means for someone taking it for weight loss. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-fractures-diabetes-only Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes Semaglutide was associated with fewer major fractures in people with type 2 diabetes and with no difference in people without it. The second group is most of the weight-loss market. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fracture risk, cohort WITH type 2 diabetes · vs empagliflozin · vs glipizide · vs usual care · 1.0 · Cohort WITHOUT diabetes: no comparison reached significance **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A target trial emulation matched people with obesity starting semaglutide to comparators 1:1 on 215 covariates. - In the cohort with type 2 diabetes, major osteoporotic fracture risk was lower: HR 0.69 against empagliflozin, 0.72 against glipizide, 0.84 against usual care. - In the cohort without type 2 diabetes, no comparison reached significance on fracture at all. - Osteoporosis diagnosis did not differ in most comparisons in either cohort. - The stratum that came back null is the one most people buying from this roster belong to. A result that holds in one group and vanishes in another is more informative than a result that holds everywhere, because the boundary tells you something about the mechanism. This study has that shape, and the boundary falls in an awkward place for anyone reading it as a reason to buy. ## How it was built The analysis used a federated network of electronic health records and a target trial emulation design: define the trial you would run, then assemble it from records that already exist. [\[1\]](https://thisglp.com/research/semaglutide-fractures-diabetes-only#ref-1) People with obesity starting semaglutide were matched one to one, on 215 covariates, against people starting an active comparator or receiving usual care. The diabetes cohort ran to between 19,824 and 93,519 matched pairs depending on the comparison and was followed three years. The non-diabetes cohort ran between 10,323 and 56,225 pairs over two years. The primary outcome was major osteoporotic fracture. Two comparators and a control condition is an unusually careful setup, and the reason it matters is visible in the results — the answer changes depending on [what you compare against](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The diabetes cohort Against empagliflozin, the hazard ratio for major osteoporotic fracture was 0.69, 95% CI 0.61 to 0.77. Against glipizide it was 0.72, 95% CI 0.63 to 0.83. Against usual care it was 0.84, 95% CI 0.76 to 0.93. All three intervals sit below one, so all three point the same way, and the spread between them is the interesting part. The weakest effect came from the comparison against usual care — the contrast where the two groups differ most in everything other than the drug. ## The cohort without diabetes Nothing. Across every comparison, no significant association with fracture was observed, all p above 0.05. Osteoporosis diagnosis did not differ significantly in most comparisons in either cohort, and exploratory looks at osteoarthritis and gout produced inconsistent patterns across comparators. That is the finding to carry away, and it is the one least likely to be repeated anywhere else. Most people buying these drugs from a telehealth seller do not have type 2 diabetes. They are in the stratum where the fracture result did not appear. Matching is not randomizing Two hundred and fifteen covariates is a lot of covariates. It is still a list somebody wrote down, and the confounders that matter in this kind of analysis are the ones nobody thought to record — how sick a patient looked, why a clinician reached for one drug rather than another, who was steady enough to keep a prescription going. A protective hazard ratio from matched records is a hypothesis with a large sample attached, not a demonstrated effect. ## Why the boundary might be real There is a plausible story, and it is worth stating as a story rather than a conclusion. Diabetes damages bone quality in ways that do not show up on a density scan, and it raises fracture risk at any given density. A drug that improves glycemic control in people with diabetes has a pathway to bone that simply does not exist in people without it. If that is what is happening, the null in the non-diabetes cohort is not a failure of power. It is the correct answer. There is an equally plausible story in which the diabetes result is confounding — sicker comparator patients, different monitoring, different falls risk — and the non-diabetes null is the honest one throughout. This study cannot separate those, and body composition is a live question in both directions, since [what the weight is made of](https://thisglp.com/research/muscle-loss-on-glp1) bears on falls as much as on bone. ## What to do with it Do not treat bone as a reason to buy or a reason not to. On the best current evidence there is no fracture signal in either direction for a person without diabetes taking these drugs, which is a genuinely reassuring kind of nothing. The people who should pay attention are those with existing osteoporosis or a fracture history, and that is a prescriber conversation rather than a product-page one — a conversation [almost no seller here gives you a way to have](https://thisglp.com/tools/what-sellers-publish). And treat the strength of this design carefully. It is far better than [a single-arm cohort](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) and it is not a randomized trial. A large matched database can produce a very precise estimate of the wrong quantity. ## Frequently asked Does semaglutide protect your bones? Only the diabetes cohort showed a lower fracture risk, and that came from matched health records rather than a randomized trial. In people with obesity but no type 2 diabetes, no comparison reached significance. Why would diabetes change the answer? One plausible explanation is that diabetes harms bone quality in ways a density scan does not capture, giving a glucose-lowering drug a pathway to bone that does not exist otherwise. The study cannot confirm that. Is a null result reassuring? Here, moderately. It means no fracture signal appeared in either direction over two years in the cohort without diabetes, across every comparison the study ran. How reliable is a target trial emulation? It is a strong observational design and not a substitute for randomization. Matching on 215 covariates cannot adjust for the reasons a clinician chose one drug over another, which is the confounding that matters most. ## Sources 1. \[1\] Huang YN, et al. (2026). Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42010367](https://pubmed.ncbi.nlm.nih.gov/42010367/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)